<DOC>
	<DOCNO>NCT00940667</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety amlodipine plus losartan amlodipine alone patient essential hypertension inadequately control amlodipine monotherapy .</brief_summary>
	<brief_title>Efficacy/Safety Amlodipine Plus Losartan Versus Amlodipine Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients 18 year age Essential hypertensive patient whose blood pressure control study ( sit DBP ≥ 90 mmHg drugtreated patient , sit DBP ≥ 95 mmHg drugnaïve patient ) Nonresponder 4 week treatment amlodipine 5 mg monotherapy ( sit DBP ≥ 90mmHg ) mean sit SBP ≥ 200 mmHg mean sit DBP ≥ 120 mmHg screen mean sit SBP ≥ 180 mmHg mean sit DBP ≥ 120 mmHg 4 week amlodipine 5 mg treatment history hypersensitivity dihydropyridines angiotensin II receptor blocker Secondary hypertensive patient suspect Uncontrolled diabetes mellitus patient Severe heart disease severe neurovascular disease Known severe malignant retinopathy Patients show clinically significant hematological finding , patient renal disease ( serum creatinine ) , patient hepatic disease ( ALT AST ) History malignancy tumor History autoimmune disease History alcohol drug abuse Positive pregnancy test , nurse mother , intention pregnancy Considered investigator appropriate participate clinical study othe reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Amlodipine</keyword>
	<keyword>Losartan</keyword>
	<keyword>hypertension</keyword>
</DOC>